Drug Trial Radar · NCT05167760
Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis
Last checked: Nov 19, 2026Latest source record: Jul 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2025
Primary completion
Nov 2027
Study completion Nov 2028
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.
Conditions
- Synkinesis
- Facial Nerve Palsy
Interventions
ApraclonidineDrug
1-2 drops per eye every 8 hours for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in synkinesis symptomsTime frame: Baseline - 20 minutes after study drug administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.